down arrow

Cyfuse Biomedical KK

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3311800001
JPY
560.00
15 (2.75%)

Dec 19

TKS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
GNI Group Ltd.
OncoTherapy Science, Inc.
Cyfuse Biomedical KK
MEDINET Co., Ltd.
SUSMED, Inc.
Stella Pharma Corp.
Chiome Bioscience, Inc.
Oncolys BioPharma, Inc.
StemCell Institute
Peptidream, Inc.
Carna Biosciences, Inc.
Why is Cyfuse Biomedical KK ?
1
Poor Management Efficiency with a low ROE of 0%
  • The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate -371.81% of over the last 5 years
3
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 24.44%, its profits have fallen by -48%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Cyfuse Biomedical KK for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Cyfuse Biomedical KK
24.44%
-0.38
63.31%
Japan Nikkei 225
25.38%
0.98
25.79%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
33.40%
EBIT Growth (5y)
-371.81%
EBIT to Interest (avg)
-84.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.04
Tax Ratio
0.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.23
EV to EBIT
-6.32
EV to EBITDA
-6.58
EV to Capital Employed
14.71
EV to Sales
84.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-232.72%
ROE (Latest)
-33.86%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET SALES(HY)

At JPY 29.42 MM has Grown at 63.06%

NET PROFIT(9M)

Higher at JPY -610.58 MM

-20What is not working for the Company
INTEREST(HY)

At JPY 5.43 MM has Grown at 20.78%

NET SALES(Q)

At JPY 5.21 MM has Fallen at -28.64%

ROCE(HY)

Lowest at -31.46%

DEBT-EQUITY RATIO (HY)

Highest at -82.93 %

RAW MATERIAL COST(Y)

Grown by 41.9% (YoY

OPERATING PROFIT MARGIN(Q)

Lowest at -4,261.78 %

PRE-TAX PROFIT(Q)

Lowest at JPY -238.9 MM

NET PROFIT(Q)

Lowest at JPY -239.53 MM

EPS(Q)

Lowest at JPY -28.96

Here's what is not working for Cyfuse Biomedical KK
Interest
At JPY 5.43 MM has Grown at 20.78%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales
At JPY 5.21 MM has Fallen at -28.64%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (JPY MM)

Debt-Equity Ratio
Highest at -82.93 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Net Sales
Lowest at JPY 5.21 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (JPY MM)

Operating Profit Margin
Lowest at -4,261.78 %
in the last five periods
MOJO Watch
Company's profit margin has deteriorated

Operating Profit to Sales

Pre-Tax Profit
Lowest at JPY -238.9 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (JPY MM)

Net Profit
Lowest at JPY -239.53 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (JPY MM)

EPS
Lowest at JPY -28.96
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (JPY)

Raw Material Cost
Grown by 41.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."